Pronunciation:
fer-ik der-eye-soe mawl-tose
Trade Name(s)
Ther. Class.
Pharm. Class.
iron supplements
Iron deficiency anemia in patients who cannot tolerate/have an unsatisfactory response to oral iron or who have chronic kidney disease (non-dialysis dependent).
A colloidal iron complex that releases iron into circulation.
Therapeutic Effect(s):
Improvement in hemoglobin concentrations.
Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: Iron is rapidly cleared from plasma and used in hemoglobin formation. Small quantities of iron excreted in urine and feces.
Half-life: 27 hr.
TIME/ACTION PROFILE (serum ferritin concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
IV | unknown | 7 days | 4 wk |
Contraindicated in:
Use Cautiously in:
Derm: rash
F and E: hypophosphatemia
GI: nausea
Misc: HYPERSENSITIVITY REACTIONS (including anaphylaxis, shock, and loss of consciousness)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Drug-Drug
None reported
IV (Adults ≥50 kg): 1000 mg as single dose; may repeat dose if iron deficiency anemia recurs.
IV (Adults <50 kg): 20 mg/kg (actual body weight) as single dose; may repeat dose if iron deficiency anemia recurs.
Solution for injection: 100 mg/mL
Monitor for signs and symptoms of hypersensitivity reactions (rash, itching, wheezing, dizziness, swelling, and breathing problems) during and after infusion for at least 30 min and until clinically stable following completion of infusion. Only administer ferric derisomaltose when personnel and equipment are immediately available for treatment of serious hypersensitivity reactions.
Lab Test Considerations:
Monitor hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during iron therapy.
Advise patient to notify health care professional immediately if signs and symptoms of hypersensitivity reactions occur.
Improved hemoglobin concentrations.